Table 16.
THIOPURINES COMPARED TO PLACEBO FOR MODERATE TO SEVERE FISTULIZING CROHN’S DISEASE | |||||||
Outcomes | Study event rates (95% CI) | Relative effect (95% CI) | Absolute effect* | No of participants (studies) | Quality of the evidence (GRADE) | ||
---|---|---|---|---|---|---|---|
Risk with placebo | Risk with thiopurines | ||||||
Achieving fistula remission (CRITICAL) | 1/5 (20%) | 1/5 (20%) | RR 1.00 (0.08 to 11.93) | 0 fewer per 1,000 (from 184 fewer to 1,000 more) | 10 (1 RCT) | ⨁◯◯◯1,2 VERY LOW | |
2 Rated down for very serious imprecision (very wide 95% CI where significant benefit or harm with thiopurines could not be excluded) | |||||||
ANTIBIOTICS COMPARED TO PLACEBO FOR MODERATE TO SEVERE FISTULIZING CROHN’S DISEASE | |||||||
Outcomes | Study event rates (95% CI) | Relative effect (95% CI) | Absolute effect* | No of participants (studies) | Quality of the evidence (GRADE) | ||
Risk with placebo | Risk with antibiotics | ||||||
Induction of clinical remission (CRITICAL) | 7/8 (87.5%) | 14/17 (82.4%) | RR 0.94 (0.67 to 1.33) | 18 fewer per 1,000 (from 210 fewer to 315 more) | 35 (1 RCT) | ⨁⨁◯◯2 LOW | |
1 Rated down for very serious imprecision (very wide 95% CI where significant benefit or harm with thiopurines could not be excluded) | |||||||
GRADE Working Group grades of evidence High quality: We are very confident that the true effect lies close to that of the estimate of the effect Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect |